Handbook of Psychooncology
Handbook of Psychooncology
复制标题
心理学手册
DOI：
10.1038/bjc.1993.361
复制
发表时间：
1993
影响因子：
8.8
通讯作者：
Basel Karger
中科院分区：
文献类型：
--
作者：
A.;J. C. Holland;J. H. Rowland;P. Hopwood;H. Rabes;P. E. Peters;K Munk;Basel Karger
447个基因。不同论文的质量各不相同，尽管其中一些只是对不同基因改变的小系列研究结果的描述，并没有强调标题“治疗的靶点”，但这本书的总体印象是好的。许多论文指出癌基因及其产物的潜在曙光是特定治疗的目标，这是令人兴奋的读物。在第一部分中，表皮生长因子受体同源物c-erbB-2是大多数论文的主题。第一篇论文很好地概述了这种受体在人类恶性疾病中的作用，以及它在人类癌症生物学中的作用。针对c-erbB-2胞外区的人源化克隆抗体的生产，其对培养的肿瘤细胞系和肿瘤异种移植瘤的抗增殖作用似乎非常有希望用于治疗涉及该受体过度表达的癌症。乳腺癌和卵巢癌患者的临床试验已经开始。C-erbB-2抗体与各种毒素、药物或同位素偶联的其他策略也将在下面的论文中讨论。它们还显示了抗体识别的表位的重要性，以便有效地抑制生长。抗EGF受体的单抗似乎在放射成像和治疗应用方面也具有临床应用价值。这些抗体似乎是EGF的拮抗剂，这种抗体现在也用于临床试验。这一部分的最后一篇论文讨论了越来越多的成纤维细胞生长因子(FGFs)及其受体作为可能的治疗靶点。最近的实验，不幸的是没有包括在书中，表明FGFs和多营养素在肿瘤血管生成中都可能是重要的。抗成纤维细胞生长因子的抗体已经与毒素偶联，并对在裸鼠体内生长的人类乳腺癌显示出潜在的抗癌活性。第二节讨论作为治疗靶点的细胞内癌基因产物，特别是ras癌蛋白。在我看来，这一部分是这本书中最令人兴奋和写得最好的部分。这一部分的第一篇论文很好地概述了细胞内抗原到达宿主免疫系统并可被宿主免疫系统看到的机制，并建立了可以制定治疗策略的框架。它包含解释MHC I类和II类途径的插图，为读者准备…
447 ing genes. The quality of the different papers varies, and although some of them are only descriptions of findings of different genetic alterations in small series with no emphasis on the title 'Targets for Therapy', the overall impression of the book is good. Many of the papers point to the dawning potential of oncogenes and their products as targets for specific therapy, and this is exciting reading. In the first section the epidermal growth-factor receptor homologue c-erbB-2 is the subject of most papers. The first paper gives a very good overview of the involvement of this receptor in human malignant diseases, and its role in the biology of human cancer. Production of humanised mono-clonal antibodies directed against the extra cellular domain of c-erbB-2, their antiproliferative effects on cultured tumour cell lines and on tumour xenografts seem very promising for the use of this agent in treatment of cancers involving overex-pression of this receptor. Clinical trials have started on both breast and ovarian cancer patients. Other strategies where antibodies to c-erbB-2 are coupled to a variety of toxins, drugs or isotopes are also considered in the following papers. They also show the importance of the epitope the antibody recognise in order to be effective in growth inhibition. Monoclonal antibodies against the EGF receptor also seem to be clinically useful both for radio-imaging and for therapeutic applications. These antibodies seem to act as antagonists of EGF, and such antibodies are now also used in clinical trials. The last paper in this section deals with the growing family of fibroblast growth factors (FGFs) and their receptors as possible targets for therapy. More recent experiments, unfortunately not included in the book, indicate that both FGFs and pleiotrophins are likely to be important in tumour angiogenesis. Antibodies to FGF have been coupled to toxins and have shown potential anti-cancer activity toward human breast cancers growing in nude mice. Section two deals with intracellular oncogene products as targets for therapy, and particularly the ras oncoproteins. This section is in my opinion the most exciting and best written part of the book. The first paper in this section gives an excellent overview of the mechanisms whereby intracel-lular antigens reach and can be seen by the host's immune system, and sets the framework on which therapeutic strategies can be devised. It contains illustrating figures explaining MHC class I and class II pathways, preparing the reader for the …